🇺🇸 ORAVESCENT Fentanyl Citrate in United States
15 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 15
Most-reported reactions
- Loss Of Consciousness — 3 reports (20%)
- Accidental Overdose — 2 reports (13.33%)
- Respiratory Distress — 2 reports (13.33%)
- Suicide Attempt — 2 reports (13.33%)
- Abdominal Pain — 1 report (6.67%)
- Amnesia — 1 report (6.67%)
- Anaemia — 1 report (6.67%)
- Anion Gap Decreased — 1 report (6.67%)
- Atrioventricular Block First Degree — 1 report (6.67%)
- Balance Disorder — 1 report (6.67%)
Other Pain Management approved in United States
Frequently asked questions
Is ORAVESCENT Fentanyl Citrate approved in United States?
ORAVESCENT Fentanyl Citrate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ORAVESCENT Fentanyl Citrate in United States?
Cephalon is the originator. The local marketing authorisation holder may differ — check the official source linked above.